PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2956879

Platelet function in acute respiratory failure.

A C Carvalho·D A Quinn·S M DeMarinis·J G Beitz·W M Zapol
View original source ↗Export metadata ↓

Abstract

To assess the role of platelets in thrombohemorrhagic complications of acute respiratory failure (ARF), we studied platelet function in 13 ARF patients admitted for intensive care, in six acutely ill intensive care patients without evidence of acute lung injury (non-ARF), and in 10 normal subjects. Platelet counts in ARF and non-ARF patients were similar to the normal range. The bleeding time of the ARF patients (8.5 +/- 0.9 min) was significantly longer (p less than 0.01) than the normal (4.8 +/- 0.2 min) but similar to non-ARF patients (5.4 +/- 0.8 min). The bleeding time prolongations in ARF patients were unrelated to platelet concentration. Platelet aggregation induced by ADP and thrombin was normal in both ARF and non-ARF patient groups. The epinephrine response was impaired in one non-ARF patient and in three ARF patients; collagen-induced aggregation was absent in two ARF patients, with a prolonged bleeding time. Levels of VIII:C and vWF in both groups of patients were similar to the normal level, but VIIIR:Ag levels in ARF patients (407 +/- 45% of normal) were higher (p less than 0.01) than in both non-ARF patients (210% +/- 10%) and normal subjects (106% +/- 4). The electrophoretic mobility of VIIIR:Ag was abnormal in ARF patients. The prolonged bleeding time in ARF patients appears to result from the qualitative and quantitative VIIIR:Ag defect. beta-Thromboglobulin levels were greater (p less than 0.01) in ARF patients (87.6 +/- 6.9 ng/ml; p less than 0.001) than in non-ARF patients (46.2 +/- 3.1 ng/ml) or in normal subjects (25.3 +/- 2.5 ng/ml p less than 0.0001). However, platelet factor 4 plasma levels in ARF patients (18 +/- 1.6 ng/ml) did not differ from those in non-ARF patients (15.0 +/- 3.0 ng/ml), but both were significantly different from normal (6.1 +/- 0.8 ng/ml). Plasma thromboxane B2 (T X B2) levels were not different from normal values in either ARF or non-ARF patients, but 6-keto-PGF1 alpha levels were significantly reduced (p less than 0.01) in ARF patients (215 +/- 43 pg/ml) compared to normal values (381 +/- 34 pg/ml). Non-ARF patients had 6-keto-PGF1 alpha levels (285 +/- 111 pg/ml) midway between the normal values and those of ARF patients. Our results suggest that in vivo platelet activation occurs in ARF. ARF patients have quantitative and qualitative platelet defects that may contribute to thrombotic and hemorrhagic complications.

Explore related subjects

6-Ketoprostaglandin F1 alphaAcute DiseaseAdolescentAdultAgedAged, 80 and overAntigensBleeding TimeBlood PlateletsFactor VIIIFemaleHumansLungMaleMiddle AgedPlatelet AggregationPlatelet CountPlatelet Factor 4Respiratory InsufficiencyThromboxane B2beta-Thromboglobulinvon Willebrand FactorComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A C Carvalho, D A Quinn, S M DeMarinis, J G Beitz, W M Zapol. 1987. Platelet function in acute respiratory failure.. https://doi.org/10.1002/ajh.2830250404

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Protective effects of CVPM on vascular endothelium in rats fed cholesterol diet.

BACKGROUND: The cardiovascular protective mixture (CVPM) is a concoction of nine Chinese traditional medicines: Dan-shen root, Szechwan lovge rhizome, Chinese angelica, Hawthorn fruit, Safflower, Peach seed, Red peony root, earthworm, and membranous milkvetch root. These medicines are used to cure cardiovascular disease in China. METHODS: Animal models were established by feeding the Sprague-Dawley (SD) rats with lipid-rich forage. Serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were measured. Malondialdehyde (MDA) content was determined to monitor lipid peroxidation. The 6-keto-prostaglandin F(1alpha)(6-keto-PGF(1alpha)) concentration was measured by radioimmunoassay to investigate the content of prostacyclin (PGI(2)). Electron microscope (JEM-1200EX) was used to observe the microstructure of the vascular endothelium. Rat aortic endothelial cell was cultured to investigate the effect of CVPM on vascular endothelial cell in vitro. RESULTS: CVPM inhibited the accumulation of TC, LDL-C, and MDA in vivo, when the rats were fed with cholesterol diet. CVPM promoted synthesizing and excreting of PGI(2), since it is capable of activating the proliferation of vascular endothelium in vitro. Electron micrographs showed that CVPM had notable protective effect on the vascular endothelium and prevented the shedding of these cells from subendothelial layer. CONCLUSIONS: CVPM could ameliorate the internal environment in which vascular endothelial cells lived, and activate the proliferation of these cells. Through these mechanisms, CVPM protect vascular endothelial cell from being harmed by excess cholesterol in vivo.

6-Ketoprostaglandin F1 alpha↗
PubMed2003

Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium.

In the present study we examined whether exercise and prostanoids have an effect on the muscle interstitial concentration of vascular endothelial growth factor (VEGF) and on the proliferative effect of muscle interstitial fluid. Dialysate from resting and exercising human skeletal muscle, obtained either during control conditions or during cyclooxygenase inhibition, was examined for its content of VEGF and for its effect on endothelial cell proliferation. Microdialysis probes with high (960 kDa) and low (5 kDa) molecular-mass cut-off membranes were placed in the vastus lateralis muscle of healthy young males. The subjects performed one-legged knee extensions (20 W). The concentration of VEGF in the 960 kDa dialysate was greater (P < 0.05) during exercise compared to at rest (67 +/- 28 vs. 230 +/- 22 pg ml-1). The rate of endothelial cell proliferation was 2.7-fold higher (P < 0.05) with the 960 kDa dialysate from resting muscle than with perfusate and was 5.8-fold higher (P < 0.05) than the perfusate value with dialysate from exercising muscle. VEGF was not enhanced with exercise in the 5 kDa dialysate, yet the exercise dialysate induced a 1.9-fold higher (P < 0.05) proliferation than the resting dialysate. Cyclooxygenase inhibition did not affect the VEGF concentration or the proliferating effect of the dialysates (P > 0.05). This study demonstrates for the first time that VEGF is present in the interstitium of human skeletal muscle and that exercise enhances the interstitial concentration of VEGF and of other, as yet unidentified, angiogenic compounds. Products of cyclooxygenase do not appear to have an effect on the release of VEGF or other proliferative agents in human skeletal muscle.

6-Ketoprostaglandin F1 alpha↗
PubMed2003

Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats.

We used rats (the Otsuka Long-Evans Tokushima Fatty strain) as a model of type 2 diabetes to find whether thromboxane (TX) A2 is involved in diabetic nephropathy, and if so, to identify where it is synthesized. We measured urinary excretion of TXB2 and 2,3-dinor-TXB2 in rats up to 60 weeks of age as markers of renal and platelet synthesis of TXA2, respectively. Some diabetic rats were given daily oral doses of OKY-046 (100 mg/kg), a TXA2 synthase inhibitor, starting when they were 10 weeks of age. Healthy Long-Evans Tokushima Otsuka rats served as the controls. Urinary excretion of protein was greater in diabetic rats at 26 weeks than in controls, and the difference increased with age. Urinary excretion of TXB2 by diabetic rats was about 150% that of controls at 14 weeks, and remained at that level. In diabetic rats, urinary excretion of 2,3-dinor-TXB2 increased with age in parallel to increases in proteinuria, but in controls, excretion of these metabolites did not change with age. In diabetic rats, OKY-046 prevented the increase in urinary excretion of both metabolites, and decreased the proteinuria. Histologic examination at 60 weeks showed intraglomerular thrombi in diabetic rats but not in controls. OKY-046 reduced intraglomerular thrombi formation and the score for glomerulosclerosis. When platelet aggregation began, more TXA2 than before was released from the thrombi that formed, and the TXA2 contributed to the progress of nephropathy in this rat model of type 2 diabetes.

6-Ketoprostaglandin F1 alpha↗